[Translation] A randomized, open-label, single-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of entacapone bidopa tablets (II) in Chinese healthy subjects under fasting and fed conditions
主要研究目的:按有关生物等效性试验的规定,选择Orion Corporation为持证商的恩他卡朋双多巴片(II)(商品名:达灵复,规格:左旋多巴100mg、卡比多巴25mg、恩他卡朋200mg)为参比制剂,对四川科伦药业股份有限公司提供的受试制剂恩他卡朋双多巴片(II)(规格:左旋多巴100mg、卡比多巴25mg、恩他卡朋200mg)进行空腹和餐后给药人体生物等效性试验,比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内,评估两种制剂在空腹和餐后给药条件下的生物等效性。
次要研究目的:观察健康志愿受试者口服受试制剂恩他卡朋双多巴片(II)(规格:左旋多巴100mg、卡比多巴25mg、恩他卡朋200mg)和参比制剂恩他卡朋双多巴片(II)(商品名:达灵复,规格:左旋多巴100mg、卡比多巴25mg、恩他卡朋200mg)的安全性。
[Translation] Main research purpose: According to the relevant provisions of bioequivalence test, Orion Corporation is selected as the licensee of Entacapone Bidopa Tablets (II) (trade name: Dalingfu, specifications: levodopa 100mg, carbidopa 25mg, entacapone 200mg) as the reference preparation, and the test preparation Entacapone Bidopa Tablets (II) (specifications: levodopa 100mg, carbidopa 25mg, entacapone 200mg) provided by Sichuan Kelun Pharmaceutical Co., Ltd. is conducted on the human bioequivalence test of fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions.
Secondary study objective: To observe the safety of oral administration of the test preparation Entacapone Bidopa Tablets (II) (Specifications: levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) and the reference preparation Entacapone Bidopa Tablets (II) (trade name: Dalingfu, specifications: levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) to healthy volunteers.